UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-00100 THERAPEUTICSMD, INC. (Exact name of Registrant as specified in its Charter) of incorporat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-00100 THERAPEUTICSMD, INC. (Exact name of Registrant as specified in its Charter) Nevada 87-0233535 (State or other juri ...

TherapeuticsMD® For Her. For Life. | --- | --- | --- | --- | |-------|-------------------------------------------------------|------------------------|-------| | | | | | | | Building the Premier Q4 2021 Earnings March 10, 2022 | Women's Health Company | | | | FOR INVESTOR PRESENTATION PURPOSES ONLY. | | | Forward-Looking Statements This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to Therapeu ...

TherapeuticsMD, Inc. (NASDAQ:TXMD) Q4 2021 Earnings Conference Call March 10, 2022 8:30 AM ET Company Participants Lisa Wilson - Investor Relations Hugh O’Dowd - Chief Executive Officer James D’Arecca - Chief Financial Officer Mark Glickman - Chief Business Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Douglas Tsao - H.C. Wainwright Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are desi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-00100 THERAPEUTICSMD, INC. (Exact name of Registrant as specified in its Charter) (State or ...

TherapeuticsMD® For Her. For Life. | --- | --- | --- | --- | |-------|---------------------------------------------------------------------------------|-------|-------| | | | | | | | Building the Premier Women's Health Company Q3 2021 Earnings November 11, 2021 | | | | | FOR INVESTOR PRESENTATION PURPOSES ONLY. | | | Forward-Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we," "our," or "the Company") may contain forward-looking statements. Forward-looking statements may includ ...

TherapeuticsMD, Inc. (NASDAQ:TXMD) Q3 Earnings Conference Call November 11, 2021 8:30 AM ET Company Participants Lisa Wilson – Investor Relations Rob Finizio – Chief Executive Officer Hugh O’Dowd – President James D'Arecca – Chief Financial Officer Mark Glickman – Chief Commercial Officer Conference Call Participants Louise Chen – Cantor Fitzgerald Annabel Samimy – Stifel Douglas Tsao – HC Wainwright Operator Good morning, ladies and gentlemen. Thank you for joining us for TherapeuticsMD, Third Quarter ...

TherapeuticsMD® For Her. For Life. ■ | --- | --- | --- | |-------|----------------------------------------------|-------| | | | | | | Building the Premier Women's Health Company | | Forward-Looking Statements | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-00100 THERAPEUTICSMD, INC. (Exact name of Registrant as specified in its Charter) of incorporati ...

TherapeuticsMD, Inc. (NASDAQ:TXMD) Q2 2021 Earnings Conference Call August 4, 2021 8:30 AM ET Company Participants Lisa Wilson – Investor Relations Rob Finizio – Chief Executive Officer James D’Arecca – Chief Financial Officer Dawn Halkuff – Chief Commercial Officer Mitchell Krassan – Chief Strategy and Performance Officer Conference Call Participants Louise Chen – Cantor Annabel Samimy – Stifel Douglas Tsao – H.C. Wainwright Operator Good morning, ladies and gentlemen. Thank you for joining us for the Ther ...